^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD27 agonist

    Related drugs:
    Apply
    Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (DIAL) (NCT03038672)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/07/2024
    Initiation :
    12/21/2018
    Primary completion :
    05/26/2023
    Completion :
    10/25/2024
    ALK • TMB • BCL2 • BCL6 • CD27 • IRF4
    |
    BCL6 rearrangement • BCL2 rearrangement • CD27 expression
    |
    Opdivo (nivolumab) • varlilumab (CDX 1127) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (Mel-65) (NCT03617328)
    Phase 1/2
    Craig L Slingluff, Jr
    Completed
    Last update posted :
    02/06/2024
    Initiation :
    11/13/2018
    Primary completion :
    01/19/2024
    Completion :
    01/19/2024
    CD4
    |
    varlilumab (CDX 1127) • Hiltonol (poly-ICLC)
    A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma (RiVa) (NCT03307746)
    Phase 2a
    University Hospital Southampton NHS Foundation ...
    Active, not recruiting
    Last update posted :
    10/12/2023
    Initiation :
    11/23/2017
    Primary completion :
    02/18/2021
    Completion :
    03/31/2024
    CD20
    |
    CD20 expression
    |
    Rituxan (rituximab) • varlilumab (CDX 1127)
    Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC (NCT04081688)
    Phase 1
    Rutgers, The State University of New Jersey
    Active, not recruiting
    Last update posted :
    07/25/2023
    Initiation :
    09/11/2019
    Primary completion :
    04/27/2022
    Completion :
    04/30/2024
    BRAF • ALK • ROS1 • LAG3 • IDO1 • CD27
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement
    |
    Tecentriq (atezolizumab) • varlilumab (CDX 1127)
    DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab (DERIVe) (NCT03688178)
    Phase 2
    Annick Desjardins, MD
    Active, not recruiting
    Last update posted :
    07/19/2023
    Initiation :
    08/26/2020
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    MGMT • IL2RA • CD4 • FOXP3 • CCL3 • ISG20
    |
    temozolomide • varlilumab (CDX 1127)
    A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers (NCT01460134)
    Phase 1
    Celldex Therapeutics
    Completed
    Last update posted :
    01/31/2018
    Initiation :
    10/01/2011
    Primary completion :
    12/01/2015
    Completion :
    10/16/2017
    BRAF • CD27
    |
    BRAF V600E • BRAF V600 • CD27 expression
    |
    varlilumab (CDX 1127)